David S. Siegel, M.D., Ph.D.
David S. Siegel, M.D., Ph.D., chief of the Division of Multiple Myeloma is one of the nation's foremost authorities on multiple myeloma, a potentially fatal blood disorder that occurs when the blood's plasma cells - which produce antibodies that attack and kill germs - grow out of control and form malignant tumors in various places in the body. Multiple myeloma can also cause anemia, a lowered resistance to infections, excessive bleeding, kidney problems, and pneumonia.
Dr. Siegel is one of 11 investigators nationwide who brought the exciting new chemotherapeutic agent Velcade to multiple myeloma patients through his clinical trials with the medication. Velcade is an injectable drug that blocks some of the chemical pathways associated with unregulated cancer cell growth. Dr. Siegel's studies have shown that Velcade slows and halts the progression of multiple myeloma. He has also been involved in clinical trials for chemotherapeutic agents Revlimid and Carfilzomib. Dr. Siegel's research has almost exclusively focused on multiple myeloma and has been published in many leading medical journals, including Nature, New England Journal of Medicine, Blood and Journal of Clinical Oncology.
Dr. Siegel is a member of the Multiple Myeloma Research Consortium (MMRC) Steering Committee. The MMRC is a unique research model that was developed to accelerate the development of novel, cutting-edge treatments for patients afflicted by multiple myeloma by catalyzing, promoting, and facilitating collaborative research between industry and academia. Click here for a list of John Theurer Cancer Center Multiple Myeloma clinical trials.
Dr. Siegel reunites with 16-year Multiple Myeloma Survivor and Patient
Recently, at the annual meeting of the American Society of Hematology (ASH), PatientPower.info reunited Dr. Siegel with former patient Jack Aiello. Dr. Siegel began treating Jack during his second transplant and enrolled him in a critical, life-saving clinical trial. Watch this rare, emotional reunion below: